Oncolytics Biotech (ONCY)

• Market cap: $62.4M
• 1 day: -8.02%
• 5 days: 3.77%
• 1 month: -10.64%
• 3 months: -33.66%
• 6 months: -20.65%
• Year to date: -12.95%
• 1 year: -34.20%
• 5 years: -76.61%
• 10 years: 72.21%

About: Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Employees: 27

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

0% more funds holding

Funds holding: 41 [Q2] → 41 (+0) [Q3]

0.36% less ownership

Funds ownership: 1.91% [Q2] → 1.55% (-0.36%) [Q3]

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

24% less capital invested

Capital invested by funds: $1.43M [Q2] → $1.1M (-$337K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 518% upside
• Avg. target: $5 518% upside
• High target: $5 518% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 31% 1-year accuracy 49 / 157 met price target

518% upside $5

Buy Reiterated

14 Nov 2024